CSF2 and adenoma: Furthermore, we demonstrated therapeutic potential by encoding EcN to produce checkpoint inhibitor therapies and cytokine GM-CSF, thereby significantly reducing adenoma burden in a model of MSS CRC through oral delivery, a disease subtype that in humans is normally unresponsive to systemically-administered checkpoint inhibitors53,54.